« Return to News | R&D Trends

Foresite closes $100M growth capital fund for late-stage healthcare companies

Friday, February 1, 2013 02:12 PM

Foresite Capital Management, a growth equity firm founded by Jim Tananbaum to finance late-stage healthcare companies, has closed its $100 million fund, Foresite Capital Fund I. The firm draws on Tananbaum and his partners' experience and expertise in building leading healthcare companies, as well as their broad private and public investment experience.

"We are marrying the best practices of growth investing with healthcare specialization," said Tananbaum, founder and managing director of Foresite Capital Management. "We are proud of our capital base, extremely excited about the prospects for healthcare growth, and believe on a risk-adjusted basis there has never been a better time to have this focus."

Foresite Capital invests in companies with disruptive, late-stage products and services in a broad range of healthcare from biotechnology, genomics and diagnostics to healthcare services and medical devices. Current portfolio companies include AcelRx Pharmaceuticals, Intarcia Therapeutics, Keryx Biopharmaceuticals, Puma Biotechnology, Solta Medical and Tarsa Therapeutics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.